1036389-90-8

Basic information

• Product Name: 1H-Isoindol-1-one, 6-aMino-5-fluoro-2,3-dihydro-
• Synonyms: 1H-Isoindol-1-one, 6-aMino-5-fluoro-2,3-dihydro-;6-aMino-5-fluoro-2,3-dihydro-1H-Isoindol-1-one;6-amino-5-fluoroisoindolin-1-one
• CAS NO: 1036389-90-8
• Molecular Formula: C₈H₇FN₂O
• Molecular Weight: 166.1523832
• Mol File: 1036389-90-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Isoindol-1-one, 6-aMino-5-fluoro-2,3-dihydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Isoindol-1-one, 6-aMino-5-fluoro-2,3-dihydro-(1036389-90-8)
• EPA Substance Registry System: 1H-Isoindol-1-one, 6-aMino-5-fluoro-2,3-dihydro-(1036389-90-8)

Safety Data

• Hazardous Substances Data: 1036389-90-8(Hazardous Substances Data)

Usage

Type of compound

Heterocyclic compound

Contains

Fluorine atom

Potential applications

Medicinal chemistry, pharmaceuticals, agrochemicals

Importance

Valuable building block for synthesis of biologically active compounds

Future research

Exploration of full potential and applications in various scientific and technological fields

Upstream product

• 1006-41-3 2-bromo-4-fluorobenzoic acid 
• 1036389-83-9 2-bromo-4-fluoro-5-nitrobenzoic acid 
• 85953-31-7 2-bromo-4-fluoro-5-nitrobenzoic acid methyl ester 
• 1036389-86-2 5-amino-2-bromo-4-fluorobenzoate methyl ester 
• 1260666-80-5 5-fluoro-2,3-dihydro-isoindol-1-one 
• 1036389-88-4 5-amino-2-cyano-4-fluorobenzoate methyl ester 

Downstream Products

• 1036389-92-0 C₁₈H₁₇FN₂O₅ 

Relevant articles and documents

(AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES

Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

ASK1 INHIBITOR COMPOUNDS AND USES THEREOF

Described herein are compounds, including pharmaceutically acceptable salts, solvates, metabolites, prodrugs thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat non

Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors

Inhibitors of Factor VIIa (FVIIa), a serine protease in the clotting cascade, have shown strong antithrombotic efficacy in preclinical thrombosis models with minimal bleeding liabilities. Discovery of potent, orally active FVIIa inhibitors has been largely unsuccessful because known chemotypes have required a highly basic group in the S1 binding pocket for high affinity. A recently reported fragment screening effort resulted in the discovery of a neutral heterocycle, 7-chloro-3,4-dihydroisoquinolin-1(2H)-one, that binds in the S1 pocket of FVIIa and can be incorporated into a phenylglycine FVIIa inhibitor. Optimization of this P1 binding group led to the first series of neutral, permeable FVIIa inhibitors with low nanomolar potency.

Sulfo-imidazole-diketone and imidazole-diketone compound and applications thereof

The invention discloses a sulfo-imidazole-diketone and imidazole-diketone compound and applications thereof. The invention provides the formula (I) compound (please see the specification) or pharmaceutical salt, solvate, prodrug, stereoisomer, tautomer and metabolite thereof, wherein X, Y, Z, R1, R2, R3 and A are defined in the formula. The invention further provides a preparing method for the compound and applications of the compound serving as an androgen receptor antagonist to treating diseases related to an androgen receptor, such as prostatic cancer, prostatic hyperplasia, acne, feather-loss disorder, hair hyperplasia, breast cancer and poor male sexual function.

A kind of diaryl hydanto?n derivatives, its preparation method, pharmaceutical composition and application

Provided are a compound as represented by formula I, or pharmaceutically acceptable salt, solvate, precursor drug, stereoisomer, tautomer, polymorph or metabolite thereof, pharmaceutical composition containing same, and uses thereof in the preparation of drugs for treating androgen receptor related diseases.

BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

The present invention provides novel bicyclic lactams derivatives, and analogues thereof, of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, B, C, W, Y, Z1, Z2, Z3, Z4, R8, and R9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

The present invention relates generally to novel macrocycles of Formula (I) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, B, C, D, L, M, W, Z1, Z2, Z3, Z4, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.